Abstract
Purpose. Grapefruit juice (GJ) is known to increase the oral bioavailability of many CYP3A-substrates by inhibiting intestinal phase-I metabolism. However, the magnitude of AUC increase is often insignificant and highly variable. Since we earlier suggested that CYP3A and P-glycoprotein (P-gp) form a concerted barrier to drug absorption, we investigated the role of P-gp in GJ-drug interactions.
Methods. The transcellular bidirectional flux of drugs that are (i) CYP3A-and/or P-gp substrates (Vinblastine, Cyclosporine, Digoxin, Fexofenadine, Losartan) or that are (ii) primary CYP3A-substrates (Felodipine, Nifedipine) was evaluated across MDCK-MDR1 cell monolayers with or without GJ, verifying monolayer integrity at all times.
Results. While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26). In contrast, no such GJ flux effect was observed with Pel and Nif, substrates of CYP3A only (2 vs. 1.7 and 1.2 vs. 1.3).
Conclusions. GJ significantly activates P-gp-mediated efflux of drugs that are substrates of P-gp, potentially partially counteracting the CYP3A-inhibitory effects of GJ.
This is a preview of subscription content, log in via an institution to check access.
REFERENCES
D. G. Bailey, J. D. Spence, C. Munoz, and J. M. O. Arnold. Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268–269 (1991).
K. S. Lown, D. G. Bailey, R. J. Fontana, S. K. Janardan, C. H. Adair, L. A. Fortlage, M. B. Brown, W. Guo, and P. B. Watkins. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:2545–2553 (1997).
M. P. Ducharme, L. H. Warbasse, and D. J. Edwards. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:485–491 (1995).
S. E. Rau, J. R. Bend, J. M. O. Arnold, L. T. Tran, J. D. Spence, and D. G. Bailey. Grapefruit juice-terfenadine single-dose interaction: Magnitude, mechanism, and relevance. Clin. Pharmacol. Ther. 61:401–409 (1997).
H. H. T. Kupferschmidt, K. E. Fattinger, H. R. Ha, F. Follath, and S. Krähenbühl. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:355–359 (1998).
P. Schmiedlin-Ren, D. J. Edwards, M. E. Fitzsimmons, K. He, K. S. Lown, P. M. Woster, A. Rahman, K. E. Thummel, J. M. Fisher, P. F. Hollenberg, and P. B. Watkins. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25:1228–1233 (1997).
U. Fuhr. Drug interactions with grapefruit juice. Extent, probable mechanisms and clinical relevance. Drug Saf. 18:251–272 (1998).
V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129–134 (1995).
R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289–294 (1998).
J. Van Asperen, O. Van Tellingen, and J. H. Beijnen. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol. Res. 37:429–435 (1998).
L. Z. Benet, C.-Y. Wu, M. F. Hebert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Contr. Rel. 39:139–143 (1996).
V. J. Wacher, L. Salphati, and L. Z. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 20:99–112 (1996).
V. J. Wacher, J. A. Silverman, Y. Zhang, and L. Z. Benet. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1322–1330 (1998).
H. Takanaga, A. Ohnishi, H. Matsuo, and Y. Sawada. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharm. Bull. 21:1062–66 (1998).
P. Langguth, S. Neuhoff, C. Regardh, and H. Spahn-Langguth. Grapefruit juice components modify the intestinal permeability of the P-glycoprotein substrate talinolol. Exp. Toxicol. Pathol. 50:117 (1998) (Abstract).
L. Z. Benet, T. Izumi, Y. Zhang, J. A. Silverman, and V. J. Wacher. Intestinal MDR transport proteins and P450 enzymes as barriers to oral drug delivery. J. Contr. Rel. In press (1999).
I. Pastan, M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford, and M. C. Willingham. A retrovirus carrying a MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. U.S.A. 85:4486–4490 (1988).
J. Hunter, M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991–14997 (1993).
Y. Zhang, and L. Z. Benet. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm. Res. 15:1520–1524 (1998).
M. Horio, K.-V. Chin, S. J. Currier, S. Goldenberg, C. Williams, I. Pastan, M. M. Gottesman, and J. Handler. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264:14880–14884 (1989).
J. M. Phang, C. M. Poore, J. Lopaczynska, and G. C. Yeh. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res. 53:5977–5981 (1993).
J. W. Critchfield, C. J. Welsh, J. M. Phang, and G. C. Yeh. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Biochem. Pharmacol. 48:1437–1445 (1994).
A. Miniscalco, J. Lundahl, C. G. Regardh, B. Edgar, and U. G. Eriksson. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261:1196–1199 (1992).
W. Schubert, U. Eriksson, B. Edgar, G. Cullberg, and T. Hedner. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur. J. Drug Metab. Pharmacokin. 20:219–224 (1995).
A. B. Shapiro and V. Ling. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250:130–137 (1997).
S. E. Bates, S. J. Currier, M. Alvarez, and A. T. Fojo. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31:6366–6372 (1992).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soldner, A., Christians, U., Susanto, M. et al. Grapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport. Pharm Res 16, 478–485 (1999). https://doi.org/10.1023/A:1011902625609
Issue Date:
DOI: https://doi.org/10.1023/A:1011902625609